What is SolveBio?
Founded in 2013, SolveBio operates at the intersection of bioinformatics and translational medicine. The company provides a sophisticated technology platform designed to index, harmonize, and link multi-omics data with clinical outcomes in real-time. By continuously processing external data sources and integrating them with proprietary internal information, SolveBio enables biotech, pharma, and diagnostic entities to maintain a comprehensive, collaborative view of targets and biomarkers. This capability is essential for modern drug discovery, where the ability to synthesize disparate data streams into a coherent narrative is a significant competitive advantage. Based in New York, the company serves as a critical infrastructure provider for organizations aiming to optimize their clinical trial designs and therapeutic development pipelines.
How much funding has SolveBio raised?
SolveBio has raised a total of $2M across 1 funding round:
Angel/Seed
$2M
Angel/Seed (2014): $2M with participation from SV Angel and Andreessen Horowitz
Key Investors in SolveBio
SV Angel
SV Angel is a long-term investment firm dedicated to supporting founders in creating impactful businesses through strategic insights and a vast network.
Andreessen Horowitz
Andreessen Horowitz is a prominent venture capital firm that invests in bold entrepreneurs building the future through technology, providing deep operational expertise.
What's next for SolveBio?
With the recent capital injection, SolveBio is poised to scale its data harmonization engine to meet the growing demand for precision medicine tools. The strategic focus will likely shift toward expanding its partner ecosystem, deepening its integration with global CDx organizations, and enhancing the real-time processing capabilities of its core platform. As the industry moves toward more data-intensive research models, SolveBio's ability to provide a unified view of molecular knowledge will be pivotal in reducing the time-to-market for novel therapeutics. The company is expected to leverage this financial runway to solidify its leadership in the bioinformatics space, ensuring that its clients remain at the forefront of biomarker discovery and clinical efficacy analysis.
See full SolveBio company page
